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Abstract  
 
Background: Poor medication adherence is associated with adverse health outcomes. Improving 
access and adherence to pharmacological therapy is important in achieving optimal health outcomes for 
Indigenous populations.  In spite of the impressive evidence base for cardiovascular pharmacotherapy, 
strategies for promoting adherence and evidence based practice are less well refined and the challenges 
for Indigenous populations are more pronounced.  Aim:  To identify factors impacting on medication 
adherence in Aboriginal Australians and identify solutions to improve the quality use of medicines.   
Method: The World Health Organization adherence model was used to classify barriers to adherence. 
Key elements of this model are (1) health care team/health system; (2) socio-economic factors; (3) 
therapy; (4) patient; and (5) condition related. Results:  Entrenched socio-economic differentials 
aggravate challenges to medication adherence among Aboriginal Australians.  Initiatives to promote 
the quality use of medicines, such as the Quality Use of Medicines Maximised for Aboriginal and 
Torres Strait Islander People (QUMAX) Program, are important strategies to promote adherence. 
Conclusions:  Medication adherence is a complex   issue and addressing modifiable factors is 
imperative to improve health outcomes.  Subsidised access to medications whether living in urban, 
regional, rural or remote areas is an important strategy in Closing the Gap.    
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Introduction  
 
Burden of cardiovascular disease among Aboriginal Australians 
 
The burden of cardiovascular disease (CVD) in Aboriginal and Torres Strait Islanders is well 
documented yet the solutions to address this problem are less apparent. 1 2  Aboriginal Australians 
suffer a disproportionate burden of CVD morbidity and mortality, including a high number of 
premature deaths.  Accessing appropriate and timely health care services is important in the context of   
high cardiovascular risk burden to improve health outcomes.    Unfortunately, many Aboriginal and 
Torres Strait Islanders present to health care facilities with advanced disease.  A recent position 
statement released by the Heart Foundation and the Australian Healthcare and Hospitals Association 
has identified disparities in hospital care for Indigenous Australians with acute coronary syndromes. 3 
This report identifies that Indigenous Australians have twice the in-hospital mortality rate and have a 
40% lower rate of angiography and a 40% lower rate of percutaneous coronary interventions.   
Reticence for reform, discrimination, racism and alienating health care environments are identified as 
barriers to accessing health care systems. 4 5  Medication adherence is defined as the extent to which 
patients take medications as prescribed by their health care providers. 6 7 Medication adherence is 
important across all areas of health care delivery but of particular  concern  is that Aboriginal and 
Torres Strait Islanders people are 19 times more likely to discharge themselves from hospital than non-
Indigenous individuals. 3 This means that within the context of advanced disease they are less likely to  
have access to evidence-based pharmacological therapy.  
 
Link between adherence with cardiovascular medications and outcomes 
Pharmacotherapy is crucial to the effective management of cardiovascular disease. 7 Failure to adhere 
with prescribed medications is a challenge for both Indigenous and non-Indigenous populations.  Poor 
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adherence to prescribed medication is well documented and associated with adverse health outcomes. 8 
The increasing recognition of the prevalence of non-adherence and the contribution to the cost and 
quality of health outcomes is increasingly of concern to clinicians, funders and policy makers. 7 Many 
medications for CVD have proven beneficial effects including reducing mortality and hospital 
readmission rates 9 yet, recent research has shown that 10% to 25% of newly diagnosed CVD patients 
discontinued their medications by six months from the start of therapy. 10  At 24 months, these rates of 
medication non-adherence doubled.  10  It is estimated that 50% to 70% of individuals with 
hypertension do not take medications as prescribed.  11, 12 The concept of medication adherence is 
complex and multifaceted and needs to be considered within the context of patient, provider and system 
issues.13 
 
Indigenous Australians face unique challenges that are underpinned by fundamental social, economic 
and health differentials.   14 These disparities and are further hindered by a mainstream health care 
system which  is often perceived as   non-welcoming by many Aboriginal Australians.  15     There are a 
range of factors inhibiting Aboriginal Australians use of medications.  The World Health Organization 
(WHO) has categorised factors impacting adherence into five dimensions which provides a useful 
framework to systematically address barriers and facilitators. Elements of this   framework are: (1) 
healthcare team/health system, (2) socioeconomic factors, (3) therapy related, (4) patient related, and 
(5) condition related. 16 This model of adherence underscores the need to consider a wide range of 
factors in addressing the causes and outcomes of poor adherence.   It is also important to consider the 
Aboriginal view of health that stems beyond the individual to focus on the individual to integrate the 
community, land, body, mind and spirit. 17The WHO model suggests that solutions are unlikely to have 
a single focus but rather a whole of system approach. Improving the health and well-being of 
Indigenous peoples underscores the salience of this approach. In addition to the poor health outcomes 
experienced by individuals and the distress to their families, it is widely accepted as result of 
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medication non-adherence, significant financial burden can result. 6  In one study cost-related 
medication restriction in people with CVD resulted in more angina and higher rates of non-fatal heart 
attacks and strokes identifying the deleterious impact of short-term, expedient solutions. 18 
 
Barriers to medications use in Aboriginal Australians 
The 1997 Keys Young Report for the Health Insurance Commission documents widespread and 
persistent barriers to accessing health care and medicines by Aboriginal people.  Barriers identified in 
this report were greater levels of poverty than for other Australians, low awareness and the 
inoperability of the safety-net scheme for Aboriginal patients. 19 Other reported obstacles were 
increased patient mobility due to social obligations, frequent non-listing of children on guardians’ 
concession cards, the “shame” involved in accessing prescriptions in culturally alienating settings, a 
lack of timely supply, inadequate support for continued use of medications and geographic isolation.19 
 
Despite the high burden of chronic disease in Aboriginal people, there is low expenditure, suggesting 
substantial under-use of medicines.20  Barriers to accessing Pharmaceutical Benefits Scheme (PBS) 
medications are evident in all areas, including metropolitan areas. Currently, Aboriginal health services   
spend hundreds of thousands dollars each year in providing medications directly to patients and  to 
cover  co-payments.20. 
 
A review of the literature identifies unique challenges for Aboriginal Australians and these are 
summarised in Table 1.  Although some of these issues are not unique to Indigenous people, there is 
often a cumulative effect of social advantage and barriers to care increasing the burden of disease and 
the need for systematic strategies to reduce inequity.  In discussing medication adherence it is also 
important to note that Aboriginal individuals and communities are not homogenous and face unique 
challenges. For example, Aboriginal people living in rural and remote and urban areas confront   issues 
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requiring tailored solutions that are appropriate to their needs.     Adherence to anticoagulation therapy 
following valvular surgery and percutaneous coronary interventions is of particular concern in people 
returning to remote communities after surgery. 21  In addition, many of the enabling strategies, such as 
susbsidised medications, are not readily available to those Aboriginal people living in urban areas. This 
identifies that a one size fits all approach is neither appropriate nor applicable in addressing medication 
issues in Australian Aboriginals. 
 
In a systematic review Haynes and colleagues  have identified  strategies to promote adherence.  22 For 
short-term drug treatments, counselling, written information and personal phone contact were found to 
promote adherence.  For long-term treatments, no simple intervention, and only some complex ones, 
led to improvements in health outcomes emphasising the complexity and challenge of promoting 
medication adherence.   A combination of  strategies such as   ensuring more convenient access to care;  
providing information, counselling and reminders;  self-monitoring, reinforcement, family therapy, 
psychological therapy, mailed communications, crisis intervention, manual telephone follow-up, and 
other forms of additional supervision or attention suggest they may improve adherence. 22  Even with 
these strategies   improvements in medication usage were not large, particularly in the longer term. In 
spite of these challenges,   as a general principle clinicians can strive to promote adherence through 
simplifying dosages, organising medications in  dosette boxes or Webster packs and conveying to the 
individual the importance of the medication. Other techniques, such as motivational interviewing, 
where ambivalence towards medication usage is explored, may also be useful.  23 It has been suggested 
that the fatalism, brought about from decades of marginalisation, exclusion and experience of tragedy, 
can alter views of engaging in positive health seeking behaviours for Aboriginal people. 24, 25  The 
stigma associated with diagnosis of a chronic condition and perception of the connotations of 
Aboriginality in interacting with mainstream services can also be a barrier to adherence. 26 The quality 
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of the relationship between the health care provider and patient   impacts on adherence, emphasing the 
importance of cultural competence training to facilitate therapeutic relationships. 27  
.   
Patient-centred strategies to improve medication uptake 
Larkin and Murray28 reported on strategies to improve medication uptake in Aboriginal Australians 
which involve patient-specific approaches such as effective communication and simplifying drug 
regimens. 28   In tailoring drug regimens, the need to take medicines regularly should be emphasised in 
patient education as it may not fit patients’ understandings of how medicines are to be used. 28  The 
importance of health literacy, the extent to which individuals have the capacity to obtain, process and 
understand   health information and services needed to make appropriate  decisions about their health  
is increasingly recognised. 29 Discussing administration of medications, clarifying concepts to elucidate 
meanings, and using educational tools to foster communication and shared understandings, particularly 
in the case of asymptomatic chronic diseases, are useful approaches. 28  Consideration should also be 
given to dosing intervals, appropriate combinations, dose forms, storage considerations, and dose 
administration aids, although keeping regimens simple makes adherence easier. 28 Empowering 
individuals to interact with health professionals and in particular engaging community pharmacists in 
promoting adherence and engagement are important considerations in improving uptake and adherence 
of medications.  
 
Initiatives for Aboriginal and Torres Strait Islander people 
Section 100 is a provision developed by the Pharmacy Guild of Australia and National Aboriginal 
Community Controlled Health Organisation (NACCHO) in 1999 to facilitate medication supply 
through community pharmacists to Aboriginal Health Services, particularly when PBS medicines 
cannot be conveniently and effectively supplied.30   Section 100 arrangements extend to all remote area 
Aboriginal health services to improve Aboriginal access to the PBS.  As part of this agreement, 
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pharmacies supply eligible Aboriginal primary health care services with PBS listed drugs on a bulk 
supply basis and are reimbursed directly by the Government. The Aboriginal health service supplies the 
medications to individual clients, through the support of the community pharmacist. 31 However, many 
Australian Aboriginals live beyond remote communities and also require strategies to promote 
medication adherence. 
 
The Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander People Program 
(QUMAX)  commenced in July 2008 and is funded by the Commonwealth Government Department of 
Health and Ageing as part of an agreement with the Pharmacy Guild of Australia, developed in 
collaboration with the National Aboriginal Community Controlled Health Organisation (NACCHO). 32   
The program focuses on medication compliance and quality use of medicines (QUM).  The QUM 
strategy (to complement Section 100) focuses on appropriate management of conditions, choosing 
suitable medicines as necessary; and the safe and effective use of medications. 33   This program 
provides structured support for QUM in Aboriginal Community Controlled Health Services (ACCHSs) 
including training for staff, cultural awareness training for community pharmacists, on-call pharmacist 
assistance to the ACCHS for urgent medication, queries or after hours dispensing of medicines, 
transport support for the delivery of prescriptions or medicines between the ACCHS and the local 
pharmacy, improved recording of PBS safety-net entitlements for ACCHS clients, Medication Access 
and Assistance Packages (MAAPs) for   patients with a high level of need, including provision of dose 
administration aids, and enhanced enrolments in diabetes and asthma subsidy programs and Home 
Medicines Reviews. 33  However, this is a time-limited program and reforms to ensure medication 
access for Aboriginal Australians need to be incorporated in sustained policy reforms. 
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A way forward to improving medication adherence for Aboriginal Australians 
Improving medication adherence is no easy task and is going to require a multi-pronged approach. As 
identified by the WHO, barriers to adherence are complex and multifaceted.  Improving medication 
adherence requires interventions at the system,   provider and patient level.   Addressing endemic social 
inequalities are fundamentally important in improving Aboriginal health. Acknowledging the rights of 
Aboriginal Australians and implementing strategies to promote equality are necessary in achieving 
reforms.  This involves fostering education and advancement of the health care profession in relating to 
Indigenous health issues.  Engaging Aboriginal communities in developing appropriate and acceptable 
policy strategies is also needed. At the system level we need to make sure that health care settings, both 
mainstream and Aboriginal Controlled Community Organisations, are welcoming and provide 
culturally safe settings so that Aboriginal people feel comfortable.  Implicit in goal is not only 
involving communities in service planning  but also building the capacity and skills of the workforce, 
both Indigenous and non-Indigenous. Ensuring medications are affordable and accessible is important, 
both for rural and urban, communities. Economic modeling suggests that subsidising medications for 
high risk populations is likely to be effective and should likely be considered. 34  Further, the tailoring 
of PBS items, such as that for nicotine replacement therapy, should be adapted to meet the unique 
needs of Aboriginal Australians and acknowledging that multiple attempts to quit are positive and more 
likely to lead to cessation in the longer term.  25, 35 It is also important to ensure that strategies are 
implemented to increase the interface between primary, secondary and tertiary care. Transitions 
between these care settings is noted as challenging in all chronic conditions – but these challenges are 
accentuated in Indigenous Australians. 
 
Strategies to promote medication adherence are summarised in Table 2. At the provider level we need 
to ensure that all health professionals are aware of the unique health needs of Aboriginal Australians 
and particularly their view of health.  This involves health care delivery systems, professional 
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organisations and educational providers to provide training in cultural competence. Within 
organisations, the presence of racism should be acknowledged, monitored and vetoed.  Ensuring 
capacity in the Indigenous workforce requires systematic planning and collaboration and is an 
important issue in improving health.  At the patient level, acknowledging the individual’s country, 
values and belief and how these influence their health seeking behaviours is crucial. Reducing the 
stigma associated with the diagnosis of many chronic conditions is also vital.  Introducing strategies, 
such as motivational interviewing, to increase the individual’s self-efficacy to engage in self-
management may be useful and decrease the sense of fatalism. 
  
The recent report of the Health and Hospital Reform Commission highlights the importance of 
improving health outcomes for Aboriginal Australians and  identifies three key issues for reform: 
1. Tackling major access and equity issues that affect health outcomes for people; 
2. Redesigning the health system so that it is better positioned to respond to emerging challenges; 
and 
3. Creating an agile and self-improving health system for long-term sustainability.36 
 
Achieving improvements in medication adherence for Aboriginal Australians is contingent on 
achieving these goals. In particular, improving the interface between the Aboriginal Community 
Controlled Organsiations and communication across health care professionals and health care 
jurisdictions is important. Increasing the capacity for Aboriginal Health workers to engage in health 
care teams and also increasing participation of Aboriginal Australians in the health workforce are 
essential solutions to improving care for Aboriginal Australians. 37, 38  Ongoing research is required to 
develop and evaluate strategies to promote culturally competent medication adherence. Ongoing trials 
of the polypill, being undertaken by the Kanyini Vascular Collaboration, are encouraging as they are 
being conducted within Australian  Aboriginal communities and appropriate to the models of care 
delivered in these settings . 39 
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Conclusions 
Addressing issues impacting on adherence is not possible without a key appreciation of  culture, 
clinical practice, policy as well as perspectives of consumers and health professionals.   Decisions 
made by government  have a pronounced effect on medication policies and as a consequence the health 
outcomes of those living with chronic conditions.40  Australian Prime Minister Kevin Rudd’s 2008 
apology to Aboriginal people and Stolen Generations emphasised the importance of improving health 
services for Indigenous people to reduce health inequities. Guaranteed access to standard medicines 
and treatment protocols is a critical step to reducing the Gap for indigenous Australians.  2 Overcoming 
challenges to optimal medication adherence require the capacity of mainstream health professionals to 
appreciate the culture  and background of Aboriginal Australians and  in particular the challenges they 
face.   In partnership with strategies to reverse social and health inequalities, engaging in an 
understanding of  social and cultural influences on patients’ health beliefs and behaviors will  
contribute to optimising  patient-provider interactions to improve medication adherence.   
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